Loading
Kymera Therapeutics, Inc. Stock: price and insider trades · United States
Insider Decl.
743
Thresholds
n/a
Buy Volume
€248M
45 ops. · all time
Sell Volume
€525M
458 ops. · all time
Who traded when
BuySaleBruce Booth131 sales
Chadwick Jeremy G29 sales
Mainolfi Nello10 sales
Gollob Jared7 sales
Goodman Noah7 sales
BVF Partners L P/il4 sales
+4 other insiders
Since the insiders bought
- -13.6%Entry US$89.68 · Close at T+90 US$77.50
- +154.9%Entry US$44.53 · Close at T+365 US$113.51
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analyst consensus: bullish or bearish?
Analysts rate Kymera Therapeutics, Inc. Strong Buy (bullish), based on 23 analysts. Average price target: US$139.35.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2025FY ended December 2025 · cache
US$112.63
Analyst consensus
23 analystsStrong buy
US$111.00Target US$139.35(+24%)US$180.00
Income statement
RevenueUS$39.2M
EBITDA-US$302.7M-772% margin
Net income-US$311.4M-285.3% margin
Valuation
PER (forward)-22.1x
P/Book6.2x
Beta1.98
Balance sheet & cash
Market capUS$9.4B
Total debtUS$82.3M
Free Cash Flow-US$234.3M
Debt / Equity5%
Profitability & ownership
ROE-24.2%
ROA-15.6%
% insiders2.1%
% institutions119.4%
Last declaration on 1 October 2026
Declarations743 total
30,000 shares@ US$111.790.036% mcap19.9% of flowCommonSEC144:0001969223-26-001047
3,525 shares@ US$111.440.0042% mcap2.9% of flowCommon StockSEC:0001193125-26-410839:1
30,000 shares@ US$2.080.0007% mcap0.5% of flowCommon StockSEC:0001193125-26-410839:0
5,506 shares@ US$112.420.0066% mcap4.6% of flowCommon StockSEC:0001193125-26-410839:2
4,876 shares@ US$113.240.0059% mcap4.1% of flowCommon StockSEC:0001193125-26-410839:3
7,601 shares@ US$114.430.0093% mcap6.5% of flowCommon StockSEC:0001193125-26-410839:4
8,230 shares@ US$115.400.010% mcap7.1% of flowCommon StockSEC:0001193125-26-410839:5
262 shares@ US$116.120.0003% mcap0.2% of flowCommon StockSEC:0001193125-26-410839:6
1,209 shares@ US$115.550.0015% mcap18.8% of flowCommon StockSEC:0001193125-26-383874:0
3,025 shares@ US$116.810.0037% mcap47.5% of flowCommon StockSEC:0001193125-26-383874:1
2,137 shares@ US$117.570.0026% mcap33.8% of flowCommon StockSEC:0001193125-26-383874:2
6,371 shares@ US$117.280.0079% mcap100.0% of flowCommon StockSEC144:0001193125-26-383667
38,000 shares0Common StockSEC:0001193125-26-318408:0
50,000 shares@ US$2.080.0011% mcap1.0% of flowCommon StockSEC:0001193125-26-297817:0
50,000 shares@ US$119.000.064% mcap59.0% of flowCommon StockSEC:0001193125-26-297817:1
80,000 shares@ US$114.290.095% mcap60.7% of flowCommonSEC144:0001969223-26-000752
3,389 shares@ US$114.670.0042% mcap34.9% of flowCommonSEC144:0001950047-26-006765
77,109 shares@ US$109.320.090% mcap100.0% of flowCommonSEC144:0001950047-26-006647
22,046 shares@ US$117.851.1% of flowCommon StockSEC:0001451612-26-000018:10
14,913 shares@ US$113.970.7% of flowCommon StockSEC:0001451612-26-000018:6
2,318 shares@ US$106.630.1% of flowCommon StockSEC:0001451612-26-000018:28
6,821 shares@ US$115.690.3% of flowCommon StockSEC:0001451612-26-000018:8
3,896 shares@ US$114.940.2% of flowCommon StockSEC:0001451612-26-000018:19
1,199 shares@ US$110.670.1% of flowCommon StockSEC:0001451612-26-000020:6
3,024 shares@ US$107.760.1% of flowCommon StockSEC:0001451612-26-000018:29
25 of 743 declarations
About Kymera Therapeutics, Inc.
Kymera Therapeutics, Inc. filings are published almost on the day of the trade: the median delay is 0 days. The record holds 737 filings, dated from August 21, 2020 to October 1, 2026, 275 of them in 2026 against 32 in 2023. Sales dominate: 494, worth EUR 569.6 million (median EUR 278,513). On June 26, 2026, BVF Partners L P/il, Director, sold EUR 78,542,690 and EUR 58,828,420, and Bruce Booth, Director, EUR 21,987,114. Booth is the top filer, with 221 filings, 214 of them sales.
The 45 purchases come to EUR 248.0 million (median EUR 1,089,398), or 8% of open-market trades. Baker Bros. Advisors LP, Director, bought EUR 135,132,145 and EUR 12,288,021 on December 11, 2025, and EUR 22,408,768 on June 30, 2025, a day when 2 filers bought for EUR 36,308,416. BVF Partners has 50 filings, 40 of them purchases. For the 45 purchases with a stored result, the 90-day median is 31.6%, with 64% positive (recorded past results, not a forecast).
Read moreShow less
Last twelve months: 318 filings, 2 purchases, 247 sales. Nello Mainolfi, Chief Executive Officer, has signed 128. The US healthcare and pharma company is listed on Nasdaq, worth USD 8.99 billion, with 32 filers.
